(Q35190115)

7 August 2017

title

Investigational therapies for psoriasis (English)

1 reference

7 August 2017

Jennifer Clay Cather

1 reference

7 August 2017

John Christian Cather

series ordinal

1 reference

7 August 2017

William Abramovits

series ordinal

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

Journal of the American Academy of Dermatology

7 August 2017

published in

1 reference

7 August 2017

1 reference

7 August 2017

issue

2 Suppl

1 reference

7 August 2017

page(s)

S133-8

1 reference

Biologic therapy for psoriasis: the new therapeutic frontier

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Development and validation of an immunoreceptor assay for simulect based on surface plasmon resonance

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases:in vivopharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Keratinocyte interleukin-10 expression is upregulated in tape-stripped skin, poison ivy dermatitis, and Sezary syndrome, but not in psoriatic plaques

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Interleukin-10 in cutaneous disorders: implications for its pathophysiological importance and therapeutic use.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

IL-10 Improves Skin Disease and Modulates Endothelial Activation and Leukocyte Effector Function in Patients with Psoriatic Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

The antipsoriatic activity of IL-10 is rather caused by effects on peripheral blood cells than by a direct effect on human keratinocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in Psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Immune-mediated side-effects of cytokines in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Interleukin-11 modulates Th1/Th2 cytokine production from activated CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Improvement in psoriasis after intradermal administration of delipidated, deglycolipidated Mycobacterium vaccae (PVAC): results of an open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Immunomodulatory effects of peptide T on Th 1/Th 2 cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Histopathological and immunohistochemical changes in psoriatic skin during peptide T treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Neutrophil functions and IL-8 in psoriatic arthritis and in cutaneous psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Initial clinical trial of a selective retinoid X receptor ligand, LGD1069

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Effects of systemic treatment with liarozole on cutaneous inflammation, epidermal proliferation and differentiation in extensive plaque psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Antiangiogenic properties of a novel shark cartilage extract: potential role in the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Systemic photodynamic therapy is a safe and effective treatment for psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

Granulocyte and monocyte adsorption apheresis for pyoderma gangrenosum

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901147-2

7 January 2021

10.1016/S0190-9622(03)01147-2

Identifiers

DOI

1 reference

7 August 2017

1 reference